Safety and efficacy of L-carnitine supplementation in patients with hematopoietic stem cell transplantatio
Not Applicable
Completed
- Conditions
- Hematological malignancy, Bone marrow failure syndrome
- Registration Number
- JPRN-UMIN000012424
- Lead Sponsor
- Sapporo Medical University School of Medicine, Department of Medical Oncology and Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria included intake of carnitine in the last two months, carnitine allergy, severe complications, pregnancy, severe mental illness.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie L-carnitine's effects on hematopoietic stem cell recovery post-transplantation?
How does L-carnitine supplementation compare to standard-of-care in reducing transplant-related complications for hematological malignancy patients?
Are there specific biomarkers that correlate with improved outcomes in bone marrow failure syndrome patients receiving L-carnitine during stem cell transplantation?
What are the potential adverse events associated with L-carnitine administration in hematopoietic stem cell transplantation and how can they be managed?
What combination therapies or alternative compounds show synergistic effects with L-carnitine in enhancing engraftment and reducing graft-versus-host disease in hematopoietic stem cell transplantation?